Clinical Trial

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-10.
Trial Details
NCT Number NCT06364904
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Bladder Cancer
Enrollment 210 participants
Start Date 2025-10
Primary Completion 2027-04-15 (estimated)
Study Completion 2029-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-02-21